| 释义 |
biopharmaceutical, a. and n. Pharmacol.
Brit. |ˌbʌɪə(ʊ)ˌfɑːməˈs(j)uːtɪkl|, U.S. |ˈˌbaɪoʊˌfɑrməˈsudək(ə)l|
Forms: 19– biopharmaceutical, 19– bio/pharmaceutical[rare]
[‹ bio- comb. form + pharmaceutical adj., after biopharmaceutics n. Compare biopharmaceutic adj.]
A. adj.
1. Of or relating to biopharmaceutics; = biopharmaceutic adj.
1965Jrnl. Pharmaceut. Sci. 54 36 (title) Biopharmaceutical investigation of nalidixic acid in man. 1966Science 11 Mar. 1310 (advt.) Pharmaceutical Biochemist–PhD. Will design and evaluate bio-pharmaceutical studies as a member of an interdisciplinary team. 1992Jrnl. Pharmacokinetics & Biopharmaceutics 20 357 Two new structural analogs..along with their parent compounds, ibufenac and ibuprofen, were evaluated for their biopharmaceutical properties. 2002European Jrnl. Pharmacol. Sci. 15 479 The overall aim of the present study was to widen our knowledge about the biopharmaceutical behaviour of novel hydroxypropyl methylcellulose (HPMC)-based two-piece capsules by comparing them with the classic hard gelatine capsules.
2. Designating or relating to biopharmaceuticals (see sense B.).
1985Business Wire (Nexis) 23 July Large-scale production of very pure and active biopharmaceutical products. 1989Jrnl. Pharmaceut. & Biomed. Anal. 7 633 (title) Quantitation of residual Escherichia coli DNA in recombinant biopharmaceutical proteins by hybridization analysis. 1997Financial Post (Canada) 1 Feb. 16/1 The whole future of..the new biopharmaceutical industry is at stake. 2002Wired Oct. 40/1 Other biopharmaceutical proteins are proving effective for treating everything from cystic fibrosis and cancer to herpes and Montezuma's revenge.
B. n. A pharmaceutical agent, typically a protein or peptide, produced by biotechnology.
1983Science 21 Oct. 356/2 (advt.) Requires Ph.D. in pharmacology or biological sciences and 10 or more years of managing the development of bio/pharmaceuticals. 1985Med. World News 25 Mar. 40 (title) Biopharmaceuticals: new technology unlocks the body's medicine cabinet. 1994Genetic Engin. News Dec. 8/1 Recombinant versions of factor VIII, the clotting factor that is deficient in those with hemophilia A (the most common variety of the disease) are approved biopharmaceuticals in the U.S. 2002Wired Oct. 40/1 The market for biopharmaceuticals is projected to hit $140 billion by 2020. |